Viking's Weight-Loss Pill Shows Lower Results
Viking Therapeutics' oral VK2735 achieved up to 12.2% weight loss in a Phase 2 trial, which was below expectations. It is safe, well-tolerated, and has mild gastrointestinal effects.
/ 1680 items
#XY↓
GoodRx & Novo Nordisk Unlock GLP-1 Access
GoodRx partnered with Novo Nordisk to offer Ozempic and Wegovy pens for $499/month to self-paying patients, expanding access for those without adequate insurance. This makes them available at over 70,000 U.S. pharmacies. Hims & Hers down.
Novo's Wegovy Secures Accelerated FDA Approval for MASH
Novo Nordisk's Wegovy (semaglutide) is now FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) with liver scarring, a significant advancement for this serious condition.
Eli Lilly's highly anticipated obesity pill yields modest results.
Lilly's new oral GLP-1, orforglipron, shows 11-12.4% weight loss in late-stage trial, short of Zepbound and Wegovy. Easier to produce and distribute than injectables, it targets wider patient access. FDA submission this year.
Novartis Pursues Avidity: A Bid for Rare Disease Dominance
Novartis targets rare disease biotech Avidity Biosciences in a $4.3B takeover bid, aiming to boost its pipeline and offset major patent cliffs.
Oscar Health Navigates Q2 Loss, Targets 2026 Profitability
Oscar Health's Q2 2025 showed a $228M loss due to sicker patients. CEO Mark Bertolini aims for 2026 profitability.